Negative Retained Earnings Carried Forward Due to Upfront Investment and Delayed Commencement of Dividends
First written in FY2019. 1 of 3 entries say "Restated". Latest entry: 2026-05-15.
1 other company's latest entry also says "Mitigated".
- 2026-05-15MitigatedShare Issuance and Disposal
「As of 31 March 2026, the Company had a deficit in retained earnings of ¥11,557,239 thousand. To strengthen its financial position, the Company will reduce stated capital and the capital reserve pursuant to Articles 447, Paragraph 1 and 448, Paragraph 1 of the Companies Act and transfer them to other capital surplus to cover the deficit, then transfer the increased other capital surplus to retained earnings pursuant to Article 452 of the Companies Act, conditional on the reductions becoming effective.」
A plan to cover the deficit in retained earnings by transferring stated capital and the capital reserve to other capital surplus and then applying the amount to the deficit was specified for the first time. The plan was conditional on approval at the Annual General Meeting of Shareholders and becoming effective on 3 August 2026; total net assets and the total number of shares outstanding would not change. - FY2022RestatedAnnual report
「当事業年度においては、会社法の規定上、配当可能な財政状態にはありませんが、株主への利益還元については重要な経営課題と認識しており、将来、現在開発中の新薬が上市され、その販売によって当期純利益が計上される時期においては、経営成績及び財政状態を勘案しながら、配当による利益還元の実施を検討したいと考えております。」
繰越利益剰余金がマイナスで配当可能な財政状態にないこと、上市・利益計上後に配当を検討する方針を再確認している。 - FY2019First statedAnnual report
「If we are unable to report net income as planned, the timing of a positive balance of retained earnings will also be delayed, which may delay the commencement of shareholder dividends.」
研究開発投資が先行し、利益計上が遅れる場合には、繰越利益剰余金のプラス化や配当開始も遅れる可能性を記載している。